DSP30
Based on 1 Customer Validation
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.27%
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
DSP30 (1 μM, 5 days) enhances the immunosuppressive function of BM-MSCs by promoting their proliferation, upregulating anti-inflammatory factors such as TGF-β1, maintaining high expression of IFN-γ and IL-10 in co-cultured T cells, and increasing the level of adenosine[1].
DSP30 (10 μg/mL, 5 days) enables CRTH2+ allergen-stimulated TH2 cells to produce IFN-γ[4].
DSP30 (0.1-1 μM, 0-72 h) significantly upregulates the expression of CD25 in B-CLL cells[5].
DSP30 (0.01-1 μM, 48-120 h) significantly enhances the killing effect of LMB-2 on B-CLL cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BM-MSC, T lymphocytes
-
Concentration:1 μM
-
Incubation Time:5 days
-
Result:Had no impact on the expression of the inflammatory cytokine IL-6.
Induced the expression of IL-1β, IL-8 and TGF-β1.
Led to a significant increase in IL-8 and VCAM expression levels with LSP (HY-D1056) stimulation.
Maintained the high expression of IFN-γ and IL-10 in T cells with upregulated BM-MSC.
-
Cell Line:B-CLL cells
-
Concentration:1 μM
-
Incubation Time:5 days
-
Result:Significantly enhanced the sensitivity of B-CLL cells to LMB-2.
Enabled the originally drug-resistant B-CLL cells to reach the clinically achievable IC50 level.
化学情報
-
性状 Solid
-
Color White to off-white
-
SMILES
N/A
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2242 KB)
参考文献
[1]. Sangiorgi B, et al. DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: A potential role of adenosine. Cytotherapy. 2016 Jul;18(7):846-59. [Content Brief]
[2]. Dun KA, et al. DSP30 and interleukin-2 as a mitotic stimulant in B-cell disorders including those with a low disease burden. Genes Chromosomes Cancer. 2018 May;57(5):260-267. [Content Brief]
[3]. Haferlach C, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007 Dec;21(12):2442-51. [Content Brief]
[4]. Annunziato F, et al. Reversal of human allergen-specific CRTH2+ T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide. J Allergy Clin Immunol. 2001 Nov;108(5):815-21. [Content Brief]
[5]. Decker T, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 2002 Feb 15;99(4):1320-6. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
DSP30 関連分類
HY-177058 関連分類
Powered by Bioz